［1］WANG Y,WANG M,WU HX,et al.Advancing to the era of cancer immunotherapy［J］.Cancer Commun (Lond)，2021，41(9):803-829.
［2］FANG Y,YU A,YE L,et al.Research progress in tumor targeted immunotherapy［J］.Expert Opin Drug Deliv，2021，18(8):1067-1090.
［3］LEE KA,LUONG MK,SHAW H,et al.The gut microbiome:what the oncologist ought to know［J］.Br J Cancer，2021，125(9):1197-1209.
［4］SAM QH,LING H,YEW WS,et al.The divergent immunomodulatory effects of short chain fatty acids and medium chain fatty acids［J］.Int J Mol Sci,2021,22(12):6453.
［5］MARKOWIAK-KOPEC P,SLIZEWSKA K.The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome［J］.Nutrients,2020,12(4):1107.
［6］RIOS-COVIAN D,RUAS-MADIEDO P,MARGOLLES A,et al.Intestinal short chain fatty acids and their link with diet and human health［J］.Front Microbiol,2016,7:185.
［7］PARADA-VENEGAS D,DELAFUENTA MK,LANDSKON G,et al.Short chain fatty acids(SCFA)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases［J］.Front Immunol,2019,10:277.
［8］KOBAYASHI M,MIKMIA D,KIMURA H,et al.Short-chain fatty acids,GPR41 and GPR43 ligands,inhibit TNF-α-induced MCP-1 expression by modulating p38 and JNK signaling pathways in human renal cortical epithelial cells［J］.Biochem Biophys Res Commun,2017,486(2):499-505.
［9］AL-ROUB A,AKHTER N,AL-SAYYAR A,et al.Short chain fatty acid acetate increases TNFα-induced MCP-1 production in monocytic cells via ACSL1/MAPK/NF-κB axis［J］.Int J Mol Sci,2021,22(14):7683.
［10］BACHEM A,MAKHLOUF C,BINGER KJ,et al.Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+T cells［J］.Immunity,2019,51(2):285-297.e5.
［11］SUN Y,YAN T,GONG G,et al.Antidepressant-like effects of Schisandrin on lipopolysaccharide-induced mice：Gut microbiota,short chain fatty acid and TLR4/NF-κB signaling pathway［J］.Int Immunopharmacol,2020,89(Pt A):107029.
［12］CHEN L,SUN M,WU W,et al.Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells' differentiation and function in induction of colitis［J］.Inflamm Bowel Dis,2019,25(9):1450-1461.
［13］SUN M,WU W,CHEN L,et al.Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis［J］.Nat Commun,2018,9(1):3555.
［14］YANG W,YU T,HUANG X,et al.Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity［J］.Nat Commun,2020,11(1):4457.
［15］NASTASI C,FREDHOLM S,WILLERSLEV-OLSEN A,et al.Butyrate and propionate inhibit antigen-specific CD8+T cell activation by suppressing IL-12 production by antigen-presenting cells［J］.Sci Rep,2017,7(1):14516.
［16］COOMBES JL,SIDDIQUI KR,ARANCIBIA-CARCAMO CV,et al.A functionally specialized population of mucosal CD103+DCs induces Foxp3+ regulatory T cells via a TGF-β-and retinoic acid-dependent mechanism［J］.The Journal of Experimental MedI CIsne,2007,204(8):1757-1764.
［17］XIU W,CHEN Q,WANG Z,et al.Microbiota-derived short chain fatty acid promotion of amphiregulin expression by dendritic cells is regulated by GPR43 and Blimp-1［J］.Biochem Biophys Res Commun,2020,533(3):282-288.
［18］TAN B,LUO W,SHEN Z,et al.Roseburia intestinalis inhibits oncostatin M and maintains tight junction integrity in a murine model of acute experimental colitis［J］.Scand J Gastroenterol,2019,54(4):432-440.
［19］MACIA L,TAN J,VIEIRA AT,et al.Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome［J］.Nat Commun,2015,6:6734.
［20］MATHEWSON ND,JENQ R,MATHEW AV,et al.Corrigendum:Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease［J］.Nat Immunol,2016,17(10):1235.
［21］ZHAO Y,CHEN F,WU W,et al.GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3［J］.Mucosal Immunol,2018,11(3):752-762.
［22］HOLOTA Y,DOVBYNCHUK T,KAJI I,et al.The long-term consequences of antibiotic therapy:Role of colonic short-chain fatty acids(SCFA) system and intestinal barrier integrity［J］.PLoS One,2019,14(8):e0220642.
［23］SINGH V,YEOH BS,WALKER RE,et al.Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation［J］.Gut,2019,68(10):1801-1812.
［24］HOYLES L,SNELLING T,UMLAI UK,et al.Microbiome-host systems interactions:protective effects of propionate upon the blood-brain barrier［J］.Microbiome,2018,6(1):55.
［25］SHIN C,LIM Y,LIM H,et al.Plasma short-chain fatty acids in patients with Parkinson's disease［J］.Mov Disord,2020,35(6):1021-1027.
［26］UNGER MM,SPIEGEL J,DILLMANN KU,et al.Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls［J］.Parkinsonism Relat Disord,2016,32:66-72.
［27］LI JM,YU R,ZHANG LP,et al.Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation:a benefit of short-chain fatty acids［J］.Microbiome,2019,7(1):98.
［28］JAKKAMSETTI V,MARIN-VALENCIA I,MA Q,et al.Brain metabolism modulates neuronal excitability in a mouse model of pyruvate dehydrogenase deficiency［J］.Sci Transl Med,2019,11(480):eaan0457.
［29］MARINO E,RICHARDS JL,MCLEOD KH,et al.Erratum:Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes［J］.Nat Immunol,2017,18(11):1271.
［30］BONAMI RH,THOMAS JW.Targeting anti-insulin B cell receptors improves receptor editing in type 1 diabetes-prone mice［J］.J Immunol,2015,195(10):4730-4741.
［31］ANTUNES KH,FACHI JL,DEPAULA R,et al.Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response［J］.Nat Commun,2019,10(1):3273.
［32］TROMPETTE A,GOLLWITZER ES,PATTARONI C,et al.Dietary fiber confers protection against Flu by shaping Ly6c-patrolling monocyte hematopoiesis and CD8+T cell metabolism［J］.Immunity,2018,48(5):992-1005.e8.
［33］ANDRADE FO,FURTADO KS,HEIDOR R,et al.Antiangiogenic effects of the chemopreventive agent tributyrin,a butyric acid prodrug,during the promotion phase of hepatocarcinogenesis［J］.Carcinogenesis,2019,40(8):979-988.
［34］XIAO X,CHEN M,XU Y,et al.Sodium butyrate inhibits neovascularization partially via TNXIP/VEGFR2 pathway［J］.Oxid Med Cell Longev,2020,2020:6415671.
［35］THIRUNAVUKKARASAN M,WANG C,RAO A,et al.Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells［J］.PLoS One,2017,12(10):e0186334.
［36］ZHANG SL,MAO YQ,ZHANG ZY,et al.Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer［J］.Theranostics,2021,11(9):4155-4170.
［37］REZASOLTANI S,YADEGAR A,ASADZADEH AH,et al.Modulatory effects of gut microbiome in cancer immunotherapy:A novel paradigm for blockade of immune checkpoint inhibitors［J］.Cancer Med,2021,10(3):1141-1154.
［38］SUN JH,QIN XH,LIU YL.Effect of sequential nutrition support on postoperative anti-tumor immune response and nutritional status in colorectal cancer patients［J］.Modern Oncology,2020,28(15):2693-2696.
［39］NOMURA M,NAGATOMO R,DOI K,et al.Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors［J］.JAMA Netw Open,2020,3(4):e202895.
［40］BOTTICELLI A,VERNOCCHI P,MARINI F,et al.Gut metabolomics profiling of non-small cell lung cancer(NSCLC) patients under immunotherapy treatment［J］.J Transl Med,2020,18(1):49.
［41］LEE SH,CHO SY,YOON Y,et al.Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice［J］.Nat Microbiol,2021,6(3):277-288.
［42］JING N,WANG L,ZHUANG H,et al.Ultrafine jujube powder enhances the infiltration of immune cells during anti-PD-L1 treatment against murine colon adenocarcinoma［J］.Cancers(Basel),2021,13(16):3987.
［43］FERRERE G,TIDJANI-ALON M,LIU P,et al.Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade［J］.JCI Insight,2021,6(2):e145207.
［44］COUTZAC C,JOUNIAUX JM,PACI A,et al.Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer［J］.Nat Commun,2020,11(1):2168.
［45］TANOUE T,MORITA S,PLICHTA DR,et al.A defined commensal consortium elIclsts CD8 T cells and anti-cancer immunity［J］.Nature,2019,565(7741):600-605.
［46］ROUTY B,LE-CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors［J］.Science,2018,359(6371):91-97.
［47］ZHAI Y,YE X,HU F,et al.Endocrine toxclIsty of immune checkpoint inhibitors:a real-world study leveraging US Food and Drug Administration adverse events reporting system［J］.J Immunother Cancer,2019,7(1):286.
［48］GU L,KHADAROO PA,SU H,et al.The safety and tolerability of combined immune checkpoint inhibitors(anti-PD-1/PD-L1 plus anti-CTLA-4):a systematic review and meta-analysis［J］.BMC Cancer,2019,19(1):559.
［49］WANG DY,SALEM JE,COHEN JV,et al.Fatal toxic effects associated with immune checkpoint inhibitors:A systematic review and Meta-analysis［J］.JAMA Oncol,2018,4(12):1721-1728.
［50］VON-ITZSTEIN MS,KHAN S,GERBER DE.Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis［J］.Clin Chem,2020,66(6):779-793.
［51］CHAPUT N,LEPAGE P,COUTZAC C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab［J］.Ann Oncol,2019,30(12):2012.
［52］WEN X,WANG HG,ZHANG MN,et al.Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation［J］.World J Gastroenterol,2021,27(21):2834-2849.
［53］CROTHEROS JW,CHU ND,NGUYEN LTT,et al.Daily,oral FMT for long-term maintenance therapy in ulcerative colitis:results of a single-center,prospective,randomized pilot study［J］.BMC Gastroenterol,2021,21(1):281.